Johnson & Johnson Innovation JLABS @ TMC, Houston.
With a lead investment from the UK-based Wellcome Trust, a premier international medical foundation, CorInnova is developing a non-blood contacting cardiac assist device. CorInnova’s device is a transformative biventricular device to treat acute heart failure. The technology will create a new paradigm for treatment. The device is designed to eliminate 40% of the adverse events associated with existing cardiac assist technologies, and may expand eligible patients by 3 to 4 times. The device may reverse the progression of HF, a blockbuster application. The device deploys minimally invasively into the pericardial sac in under 30 seconds, and has shown the ability to increase cardiac output by up to 50%. Addressable markets are up to $8 billion.
Company’s Keywords:
heart failure, minimally invasive, biventricular cardiac assist device, nonblood contacting, cardiovascular, congestive heart failure, medical device, active implantable medical device, cardiac assist, heart assist, soft robotics, mechanical circulatory support
12
medical devices
2400000
Gmail, Google Apps, YouTube, Wix, Mobile Friendly, Varnish